64Cu-DOTATATE PET/CT 与神经内分泌肿瘤患者总生存期及无进展生存期的预测
该研究纳入两项前瞻性研究中接受 64Cu-DOTATATE PET/CT 生长抑素受体显像的 128 例神经内分泌肿瘤患者,随访中位 73 个月。结果显示 64Cu-DOTATATE SUVmax 最佳截断值 43.3 与无进展生存期相关,风险比为 0.56,但未找到预测总生存期的显著截断值,且 24 个月无进展生存期预测准确性仅为中等(57%)。
要点
- 64Cu-DOTATATE PET/CT 显示的肿瘤生长抑素受体密度对无进展生存期有预后价值,但对总生存期无预后价值。
- SUVmax 最佳截断值 43.3 用于预测无进展生存期,风险比为 0.56(95%CI 0.38-0.84)。
- 24 个月无进展生存期预测准确性为中等(57%),限制了其在个体患者层面的应用价值。
核心结论
- 在这项首次报告 64Cu-DOTATATE PET/CT 与神经内分泌肿瘤患者结局关联的研究中,肿瘤生长抑素受体密度对无进展生存期有预后价值,但对总生存期无预后价值。
- 64Cu-DOTATATE PET/CT 生长抑素受体显像后 24 个月无进展生存期预测准确性为中等,限制了其在个体患者层面的价值。
研究设计与样本
- 研究评估了两项前瞻性研究中接受 64Cu-DOTATATE PET/CT 生长抑素受体显像的神经内分泌肿瘤患者,共纳入 128 例。
- 每位患者的示踪剂摄取以最大 SUV(SUVmax)确定,采用 Kaplan-Meier 分析及 log-rank 检验评估 64Cu-DOTATATE SUVmax 对总生存期和无进展生存期的预测价值。
- 计算了 64Cu-DOTATATE PET/CT 后 24 个月结局预测的特异性、敏感性和准确性。
主要发现
- 128 例患者中位随访 73 个月(范围 1-112 个月),随访期间 112 例出现疾病进展,69 例死亡。
- 预测无进展生存期的 64Cu-DOTATATE SUVmax 最佳截断值为 43.3,SUVmax 高于 43.3 的患者风险比为 0.56(95%CI 0.38-0.84)。
- 未找到预测总生存期的显著截断值。
- 在调整年龄、性别、原发肿瘤部位和肿瘤分级的多元 Cox 回归中,SUVmax 截断值对无进展生存期的风险比为 0.50(范围 0.32-0.77)。
- 64Cu-DOTATATE PET/CT 后 24 个月预测无进展生存期的准确性为中等(57%)。
关键数值与推荐
- 预测无进展生存期的 64Cu-DOTATATE SUVmax 最佳截断值为 43.3。
- SUVmax 高于 43.3 的患者无进展生存期风险比为 0.56(95%CI 0.38-0.84)。
- 调整年龄、性别、原发肿瘤部位和肿瘤分级后,SUVmax 截断值对无进展生存期的风险比为 0.50(范围 0.32-0.77)。
- 64Cu-DOTATATE PET/CT 后 24 个月预测无进展生存期的准确性为 57%。
局限性
- 64Cu-DOTATATE PET/CT 生长抑素受体显像后 24 个月无进展生存期预测准确性为中等,限制了其在个体患者层面的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Overexpression of somatostatin receptors (SSTRs) in patients with neuroendocrine neoplasms (NENs) is used for both diagnosis and treatment. Receptor density may reflect tumor differentiation and thus be associated with prognosis. Noninvasive visualization and quantification of SSTR density is possible by SSTR imaging (SRI) using PET. Recently, we introduced 64Cu-DOTATATE for SRI, and we hypothesized that uptake of this tracer could be associated with overall survival (OS) and progression-free survival (PFS). Methods: We evaluated patients with NENs who underwent 64Cu-DOTATATE PET/CT SRI in 2 prospective studies. Tracer uptake was determined as the maximal SUV (SUVmax) for each patient. Kaplan-Meier analysis with log-rank was used to determine the predictive value of 64Cu-DOTATATE SUVmax for OS and PFS. Specificity, sensitivity, and accuracy were calculated for prediction of outcome at 24 mo after 64Cu-DOTATATE PET/CT. Results: In total, 128 patients with NENs were included and followed for a median of 73 mo (range, 1-112 mo). During follow-up, 112 experienced disease progression, and 69 died. The optimal cutoff for 64Cu-DOTATATE SUVmax was 43.3 for prediction of PFS, with a hazard ratio of 0.56 (95% confidence interval, 0.38-0.84) for patients with an SUVmax of more than 43.3. However, no significant cutoff was found for prediction of OS. In multiple Cox regression adjusted for age, sex, primary tumor site, and tumor grade, the SUVmax cutoff hazard ratio was 0.50 (range, 0.32-0.77) for PFS. The accuracy was moderate for predicting PFS (57%) at 24 mo after 64Cu-DOTATATE PET/CT. Conclusion: In this first study to report the association of 64Cu-DOTATATE PET/CT and outcome in patients with NENs, tumor SSTR density as visualized with 64Cu-DOTATATE PET/CT was prognostic for PFS but not OS. However, the accuracy of prediction of PFS at 24 mo after 64Cu-DOTATATE PET/CT SRI was moderate, limiting the value on an individual-patient basis.
引用
- Carlsen EA, Johnbeck CB, Binderup T, et al. 64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. J Nucl Med. 2020. PMID: 32111685. doi:10.2967/jnumed.119.240143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。